Jennison Associates LLC Sells 1,704,207 Shares of Sanofi (NASDAQ:SNY)

Jennison Associates LLC cut its position in Sanofi (NASDAQ:SNY) by 89.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 200,238 shares of the company’s stock after selling 1,704,207 shares during the quarter. Jennison Associates LLC’s holdings in Sanofi were worth $9,657,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SNY. AQR Capital Management LLC purchased a new position in shares of Sanofi during the second quarter valued at approximately $344,000. The Manufacturers Life Insurance Company raised its position in shares of Sanofi by 27.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,528 shares of the company’s stock worth $1,530,000 after acquiring an additional 6,756 shares in the last quarter. SG Americas Securities LLC raised its holdings in Sanofi by 3.8% in the third quarter. SG Americas Securities LLC now owns 15,068 shares of the company’s stock worth $868,000 after purchasing an additional 548 shares in the last quarter. GAMMA Investing LLC lifted its position in Sanofi by 51.2% during the third quarter. GAMMA Investing LLC now owns 4,632 shares of the company’s stock valued at $267,000 after acquiring an additional 1,569 shares during the last quarter. Finally, Atomi Financial Group Inc. boosted its position in shares of Sanofi by 26.6% in the 3rd quarter. Atomi Financial Group Inc. now owns 19,932 shares of the company’s stock worth $1,149,000 after purchasing an additional 4,189 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on SNY. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Price Performance

Sanofi stock opened at $53.50 on Thursday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.74 and a current ratio of 1.46. The company’s 50 day simple moving average is $49.54 and its 200-day simple moving average is $52.35. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The company has a market capitalization of $135.77 billion, a price-to-earnings ratio of 21.49, a price-to-earnings-growth ratio of 1.26 and a beta of 0.57.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.58% and a net margin of 12.77%. As a group, equities research analysts expect that Sanofi will post 4.34 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.